The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies

Area of Science:

• Immunology
• Biotechnology
• Gene Therapy

Background:

• Adenoviruses (Ad) are common pathogens, typically causing mild infections.
• Adenovirus-based platforms are advantageous for gene therapy, vaccines, and oncology due to genetic manipulability, production scalability, and safety.
• Immune responses, both pre-existing and induced by vectors, significantly hinder the efficacy of adenovirus-based therapies.

Purpose of the Study:

• To review the challenges posed by innate and adaptive immune responses to adenovirus (Ad) vectors.
• To summarize current strategies for overcoming pre-existing and anti-vector immunity.
• To discuss the outcomes and future applications of these strategies.

Main Methods:

• Review of existing literature on adenovirus immunity and therapeutic strategies.
• Analysis of innate and adaptive immune responses against adenoviral vectors.
• Synthesis of approaches to mitigate immune challenges in gene therapy and related applications.

Main Results:

• Pre-existing immunity in the population and rapid anti-vector immune responses are major obstacles.
• Various strategies have been developed to address these immune challenges.
• These strategies aim to improve the therapeutic impact of adenovirus-based treatments.

Conclusions:

• Overcoming immune responses is critical for the successful clinical application of adenovirus-based therapies.
• Continued research into immunomodulation and vector design is essential.
• Future applications may see enhanced efficacy and broader use of adenovirus vectors in medicine.